| |
| |
|
| Insider
Information: |
Schilke Tobin |
| Relationship: |
CFO |
| City: |
South San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
240,414 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$640,845 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
240,414 |
|
|
| Total
Value |
$640,845 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
3
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
3
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-3.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -174.7%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Achaogen Inc |
AKAO |
Chief Financial Officer |
2018-06-26 |
47,748 |
2016-07-05 |
0 |
Premium* |
|
|
Revance Therapeutics, Inc. |
RVNC |
CFO |
2024-03-18 |
192,666 |
2018-11-05 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
52 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2018-11-05 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
18,000 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2019-12-15 |
4 |
D |
$15.99 |
$24,880 |
D/D |
(1,556) |
22,367 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2019-12-31 |
4 |
A |
$10.82 |
$5,453 |
D/D |
504 |
22,871 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2019-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
23,000 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2019-06-28 |
4 |
A |
$11.02 |
$10,176 |
D/D |
923 |
23,923 |
0 |
- |
|
| AKAO |
Achaogen Inc |
Chief Financial Officer |
• – – |
2017-01-26 |
4 |
S |
$16.78 |
$16,025 |
D/D |
(955) |
26,045 |
0 |
- |
|
| AKAO |
Achaogen Inc |
Chief Financial Officer |
• – – |
2016-07-05 |
4 |
A |
$0.00 |
$0 |
D/D |
27,000 |
27,000 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2020-02-15 |
4 |
D |
$25.33 |
$14,590 |
D/D |
(576) |
38,795 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2020-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
16,500 |
39,371 |
0 |
- |
|
| AKAO |
Achaogen Inc |
Chief Financial Officer |
• – – |
2017-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
13,500 |
39,545 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2020-06-30 |
4 |
A |
$13.80 |
$10,526 |
D/D |
763 |
39,558 |
0 |
- |
|
| AKAO |
Achaogen Inc |
Chief Financial Officer |
• – – |
2017-06-12 |
4 |
S |
$21.53 |
$44,481 |
D/D |
(2,066) |
40,119 |
0 |
- |
|
| AKAO |
Achaogen Inc |
Chief Financial Officer |
• – – |
2018-02-21 |
4 |
S |
$10.67 |
$11,822 |
D/D |
(1,108) |
40,185 |
0 |
- |
|
| AKAO |
Achaogen Inc |
Chief Financial Officer |
• – – |
2018-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
6,880 |
47,065 |
0 |
- |
|
| AKAO |
Achaogen Inc |
Chief Financial Officer |
• – – |
2018-06-11 |
4 |
S |
$11.95 |
$24,940 |
D/D |
(2,087) |
47,186 |
0 |
- |
|
| AKAO |
Achaogen Inc |
Chief Financial Officer |
• – – |
2018-06-26 |
4 |
S |
$9.59 |
$2,858 |
D/D |
(298) |
47,748 |
0 |
- |
|
| AKAO |
Achaogen Inc |
Chief Financial Officer |
• – – |
2018-06-26 |
4 |
A |
$0.00 |
$0 |
D/D |
860 |
48,046 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2020-12-15 |
4 |
D |
$26.75 |
$41,623 |
D/D |
(1,556) |
48,306 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2023-03-01 |
4 |
AS |
$33.50 |
$107,234 |
D/D |
(3,201) |
49,390 |
0 |
% |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2020-09-30 |
4 |
D |
$25.14 |
$136,912 |
D/D |
(5,446) |
49,862 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2023-02-15 |
4 |
D |
$33.21 |
$69,243 |
D/D |
(2,085) |
52,591 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2023-02-01 |
4 |
AS |
$34.60 |
$110,755 |
D/D |
(3,201) |
54,676 |
0 |
% |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2020-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
15,750 |
55,308 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2023-01-20 |
4 |
AS |
$31.00 |
$31,000 |
D/D |
(1,000) |
57,877 |
0 |
% |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2023-01-09 |
4 |
AS |
$25.00 |
$100,525 |
D/D |
(3,701) |
58,877 |
0 |
% |
|
52 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
